FDA Advisory Panel Votes on Avandia
A Food and Drug Administration advisory panel recently voted to keep the GlaxoSmithKline drug Avandia on the market. The diabetes medication has come under fire recently for allegations that it can increase the risk of heart attack for users. The panel first voted 21-4 that Avandia is more likely to cause heart attack than its […]
